Ben Adams

Ben Adams is a seasoned reporter with a focus on the biotechnology and pharmaceutical sectors. On March 18, 2024, he published three notable articles. His first article of the day, released at 11:05 am, discussed the potential broad uses of immunotherapy in treating endometrial cancer, highlighting ongoing debates within AstraZeneca and GSK. Shortly thereafter, at 11:49 am, Adams reported on Bluebird bio’s financial maneuver, securing a crucial loan from Hercules Capital to support the launch of three gene therapies. Later that afternoon, at 3:25 pm, he covered a significant milestone in gene therapy, detailing Orchard’s FDA approval for the first MLD gene therapy in the US following its acquisition by Kyowa Kirin. Adams’ reports are valued for their timely and insightful analysis of key industry events.